Not necessarily. We got caught up in timing, so the long term gain outweighs short term pain. It is unfortunate OTC markets punishes a company for doing the right thing. They should be allowed to put out unaudited numbers to maintain compliance with the pink regulations while in a transitory phase. But, apparently, you lose your queue with OTC and costs you even more time and money. OTC rules, its stupid but it is what it is.
Short term limbo, but not forever. AMFE delivers over time, its why the revenues keep increasing Y over Y and why the long outlook for AMFE is strong and positive.
News 
Market Data 
Discover 
